

Risperidone Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Route Of Administration (Injectable, Oral, Parenteral), By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others), By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition, 2020-2030F

<https://marketpublishers.com/r/R09A59342239EN.html>

Date: February 2025

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: R09A59342239EN

Abstracts

Global Risperidone Market was valued at USD 605.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.10% through 2030. The global Risperidone market is a crucial segment of the pharmaceutical industry, driven by the demand for effective treatments of psychiatric disorders. Risperidone, an antipsychotic medication, plays a central role in managing conditions like schizophrenia, bipolar disorder, and certain mood disorders.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The rising prevalence of mental health disorders is a significant driver of the global Risperidone market, influencing demand, market expansion, and investment in mental health treatments. Risperidone, an antipsychotic medication primarily used to treat conditions such as schizophrenia, bipolar disorder, and irritability associated with autism, has seen increased adoption due to the growing burden of mental health issues worldwide. Mental health disorders, including schizophrenia, bipolar disorder, and

autism spectrum disorders, are becoming more prevalent globally due to factors such as urbanization, lifestyle changes, stress, and greater awareness and diagnosis of these conditions. According to the World Health Organization (WHO), Approximately 1 in 4 of the global population will experience mental or neurological disorders at some stage in their lives. Currently, around 450 million individuals are affected by these conditions, making mental health disorders one of the primary contributors to ill-health and disability worldwide. Increased awareness campaigns and educational initiatives by governments, healthcare organizations, and advocacy groups have reduced the stigma surrounding mental health issues. As a result, more individuals are seeking diagnosis and treatment, leading to higher prescription rates of medications like Risperidone. This cultural shift has expanded the addressable market for antipsychotic drugs, driving growth in the Risperidone market.

Key Market Challenges

Regulatory Hurdles and Safety Concerns

The pharmaceutical industry operates within a heavily regulated framework, and Risperidone is no exception. Risperidone, like all medications, undergoes rigorous safety evaluations. Concerns about side effects, particularly metabolic and neurological issues, have led to increased scrutiny. Regulatory bodies often require pharmaceutical companies to update safety labels or provide additional warnings. As Risperidone loses patent protection in various regions, generic versions become available. Generic competition can lead to price erosion, reducing the revenue potential for branded Risperidone. These dynamic challenges market growth, as lower prices may affect profitability.

Key Market Trends

Increasing Focus on Mental Health Awareness and Treatment

Governments, international organizations, and healthcare advocacy groups have launched global mental health initiatives. These programs aim to raise awareness, reduce stigma, and improve access to mental health treatment. As a result, more individuals are seeking help for psychiatric disorders, driving the demand for medications like Risperidone. The integration of telehealth and digital mental health services has expanded access to psychiatric care. Remote consultations and telemedicine platforms facilitate diagnosis and treatment, including the prescription of Risperidone. This trend has gained further prominence during the COVID-19 pandemic.

A shift towards community-based mental health services ensures that individuals have easier access to care. This trend promotes early diagnosis and treatment, leading to increased utilization of psychiatric medications like Risperidone.

Key Market Players

Otsuka Pharmaceutical Co., Ltd

AbbVie Inc

Dr. Reddy's Laboratories Ltd

Pfizer Inc

Endo International plc

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

Viatis Inc

Novartis AG

Lupin Limited

Report Scope:

In this report, the Global Risperidone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Risperidone Market, By Route Of Administration:

Injectable

Oral

Parenteral

Risperidone Market, By Application:

Schizophrenia

Bipolar Disorder

Irritability Associated with Autistic Disorder

Others

Risperidone Market, By End-Users:

Hospitals

Homecare

Specialty Clinics

Ambulatory Surgical Centers

Others

Risperidone Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customizations:

Global Risperidone market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. RISPERIDONE MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Route Of Administration (Injectable, Oral, Parenteral)
 - 5.2.2. By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others)
 - 5.2.3. By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical

Centers, Others)

5.2.4. By Region

5.2.5. By Company (2024)

5.3. Market Map

6. NORTH AMERICA RISPERIDONE MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Route of Administration

6.2.2. By Application

6.2.3. By End User

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Risperidone Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Route of Administration

6.3.1.2.2. By Application

6.3.1.2.3. By End User

6.3.2. Canada Risperidone Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Route of Administration

6.3.2.2.2. By Application

6.3.2.2.3. By End User

6.3.3. Mexico Risperidone Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Route of Administration

6.3.3.2.2. By Application

6.3.3.2.3. By End User

7. EUROPE RISPERIDONE MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Route of Administration
 - 7.2.2. By Application
 - 7.2.3. By End User
 - 7.2.4. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany Risperidone Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Route of Administration
 - 7.3.1.2.2. By Application
 - 7.3.1.2.3. By End User
 - 7.3.2. United Kingdom Risperidone Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Route of Administration
 - 7.3.2.2.2. By Application
 - 7.3.2.2.3. By End User
 - 7.3.3. Italy Risperidone Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Route of Administration
 - 7.3.3.2.2. By Application
 - 7.3.3.2.3. By End User
 - 7.3.4. France Risperidone Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Route of Administration
 - 7.3.4.2.2. By Application
 - 7.3.4.2.3. By End User
 - 7.3.5. Spain Risperidone Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value

- 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Route of Administration
 - 7.3.5.2.2. By Application
 - 7.3.5.2.3. By End User

8. ASIA-PACIFIC RISPERIDONE MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Route of Administration
 - 8.2.2. By Application
 - 8.2.3. By End User
 - 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Risperidone Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Route of Administration
 - 8.3.1.2.2. By Application
 - 8.3.1.2.3. By End User
 - 8.3.2. India Risperidone Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Route of Administration
 - 8.3.2.2.2. By Application
 - 8.3.2.2.3. By End User
 - 8.3.3. Japan Risperidone Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Route of Administration
 - 8.3.3.2.2. By Application
 - 8.3.3.2.3. By End User
 - 8.3.4. South Korea Risperidone Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Route of Administration

8.3.4.2.2. By Application

8.3.4.2.3. By End User

8.3.5. Australia Risperidone Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Route of Administration

8.3.5.2.2. By Application

8.3.5.2.3. By End User

9. SOUTH AMERICA RISPERIDONE MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Route of Administration

9.2.2. By Application

9.2.3. By End User

9.2.4. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Risperidone Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Route of Administration

9.3.1.2.2. By Application

9.3.1.2.3. By End User

9.3.2. Argentina Risperidone Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Route of Administration

9.3.2.2.2. By Application

9.3.2.2.3. By End User

9.3.3. Colombia Risperidone Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

- 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Route of Administration
 - 9.3.3.2.2. By Application
 - 9.3.3.2.3. By End User

10. MIDDLE EAST AND AFRICA RISPERIDONE MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Route of Administration
 - 10.2.2. By Application
 - 10.2.3. By End User
 - 10.2.4. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Risperidone Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Route of Administration
 - 10.3.1.2.2. By Application
 - 10.3.1.2.3. By End User
 - 10.3.2. Saudi Arabia Risperidone Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Route of Administration
 - 10.3.2.2.2. By Application
 - 10.3.2.2.3. By End User
 - 10.3.3. UAE Risperidone Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Route of Administration
 - 10.3.3.2.2. By Application
 - 10.3.3.2.3. By End User

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Developments

12.2. Product Launches

12.3. Mergers & Acquisitions

13. GLOBAL RISPERIDONE MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

15. COMPETITIVE LANDSCAPE

15.1. Otsuka Pharmaceutical Co., Ltd

15.1.1. Business Overview

15.1.2. Product & Service Offerings

15.1.3. Recent Developments

15.1.4. Financials (If Listed)

15.1.5. Key Personnel

15.1.6. SWOT Analysis

15.2. AbbVie Inc

15.3. Dr. Reddy's Laboratories Ltd

15.4. Pfizer Inc

15.5. Endo International plc

15.6. Teva Pharmaceutical Industries Ltd

15.7. Sun Pharmaceutical Industries Ltd

15.8. Viatris Inc

15.9. Novartis AG

15.10. Lupin Limited

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Risperidone Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Route Of Administration (Injectable, Oral, Parenteral), By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others), By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/R09A59342239EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R09A59342239EN.html>